Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001209191-20-064659

Chief Executive Officer sold 4,999 shares at $25.00 ($124,975)

  • Chief Executive Officer acquired 4,999 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Ballal Rahul D. · Chief Executive Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2020-12-17 Exercise or conversion : show line 1 in the form +4,999 $3.15 $15,747 4,999 D
2020-12-17 Sale : show line 2 in the form −4,999 $25.00 $124,975 0 D
Open-market sales · 4,999 sh · avg $25.00 · $124,975

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2020-12-17 Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) −4,999 263,999 D
Loading xslF345X03/doc4.xml…